Comparative Pharmacology
Head-to-head clinical analysis: NALOXONE HYDROCHLORIDE versus ZIMHI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NALOXONE HYDROCHLORIDE versus ZIMHI.
NALOXONE HYDROCHLORIDE vs ZIMHI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at mu, kappa, and delta opioid receptors, reversing opioid-induced respiratory depression and analgesia.
Opioid receptor antagonist; reverses opioid effects by competitively binding to mu-opioid receptors.
0.4 mg to 2 mg intravenous, intramuscular, or subcutaneous every 2 to 3 minutes as needed for opioid reversal; may repeat until response achieved. For continuous infusion, 0.25-6.25 mg/hour IV.
5 mg intramuscularly every 2-3 minutes as needed; maximum 3 doses.
None Documented
None Documented
Terminal elimination half-life is 1–1.5 hours in adults; shorter in neonates (approx. 3 hours due to immature clearance). Clinically, rapid decline limits duration of antagonism.
Terminal half-life: 2.5-4 hours; clinical context: short duration requires repeat dosing for sustained opioid effects.
Primarily hepatic metabolism (glucuronidation) with renal excretion of metabolites. ~70% as naloxone-3-glucuronide in urine, <5% unchanged. Minor fecal elimination (<10%).
Renal: 30-35% unchanged; biliary/fecal: 50-60% as metabolites.
Category A/B
Category C
Opioid Antagonist
Opioid Antagonist